DLL3: an emerging target in small cell lung cancer

Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, and very few patients survive more than 5 years from diagnosis. Treatment options fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Owen, Dwight H., Giffin, Michael J., Bailis, Julie M., Smit, Marie-Anne Damiette, Carbone, David P., He, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582566/
https://www.ncbi.nlm.nih.gov/pubmed/31215500
http://dx.doi.org/10.1186/s13045-019-0745-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582566/
https://www.ncbi.nlm.nih.gov/pubmed/31215500
http://dx.doi.org/10.1186/s13045-019-0745-2

Ejemplares similares